article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

To help financially weak citizens gain access to affordable healthcare, the Pradhan Mantri Jan Arogya Yojana (PMJAY) was launched in 2018, providing about 500 million Indians with a ₹5 lakh family health insurance cover that include coverage for 1,400 medical procedures as well as critical diseases like prostate cancer.

article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CADTH advisory panel consults on framework for pan-Canadian formulary

Pharma in Brief

In Canada, coverage for prescription drugs exists through an array of public and private drug plans. The Panel’s mandate did not include governance structures, financing, patient eligibility, or the interplay between public and private insurance plans. Background. a formulary); and. a formulary); and. Drug cost was not a consideration.

article thumbnail

The ACA Contraceptive Mandate (Part 2)

FDA Law Blog: Biosimilars

Since that blog post, an important step forward was the decoupling of the coverage requirement from the FDA Birth Control Guide in the guidance provided by the Department to plans and issuers.

article thumbnail

First Drugs Selected for Price Negotiations Under The Inflation Reduction Act To Be Announced Next Week: A Recap of What That Means – The Drug Price Negotiation Program and Pending Legal Challenges

Big Molecule Watch

Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.

article thumbnail

Top Performing Drug – Enbrel (June Edition)

PharmaShots

Some of the alternative drugs for Enbrel include: Enbrel’s Biosimilars6 As Enbrel has a long journey in the market it is already facing competition from biosimilars in the US and other countries. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. Clinicaltrial.gov 4.